PubMed Health⌕ Search

Biomedical subjects

H van Cauwenberge

Publications and source records attributed to H van Cauwenberge.

At least 19 recordsLinked to original sources
PubMed1984

Pulmonary lymphangiomyomatosis.

Pulmonary lymphangiomyomatosis is a rare disease of smooth muscle proliferation in the walls of lymphatic vessels and in the interstitial areas of the lungs. It only affects women of reproductive age. The majority of patients die from respiratory failure within 10 years. A new observation of pulmonary lymphangiomyomatosis is reported in a woman of 36 years. The disease was discovered at an advanced stage of respiratory failure. Left-sided pleurectomy and treatment with medroxy-progesterone and tamoxifen did not improve the patient's condition.

Adult↗
PubMed1976

18-hydroxylated steroids in human hypertension - clinical study.

The detection of two unknown urinary steroids called x and y in various patients was previously reported. Compound x was tentatively characterized as a derivative of dihydro-18-hydroxy-DOC with two additional polar groups. In this communication clinical observations of a set of 25 hypertensive patients are presented. Compound x alone was found in 4 cases, compound y alone 4 cases and both compound x and y in 5 cases. In several other cases, hypokalemia and/or a decreased urinary Na+/K+ ratio were found.

18-Hydroxydesoxycorticosterone↗
PubMed1976

Metabolism of hydroxyethylrutosides (HR): metabolism of [14C]-HR in man.

1. following oral administration of a [14C]-hydroxyethylrutoside (Paroven, Venoruton) preparation (HR) to three subjects, 3.05--5.97% of the administered [14C] was excreted in urine. Unchanged urinary [14C]-hydroxyethylrutosides represented 1.57--1.96% of the total dose. 2. Significant levels of [14C] were detected in plasma within 1 h of oral administration of HR. Peak levels were observed from 2--9 h. 3. The presence in urine of [14C]-3',4',5,7-tetra-O-(beta-hydroxyethyl)rutoside, [14C]-3',4',7-tri-O-(beta-hydroxyethyl)rutoside and [14C]-4',7-di-O-(beta-hydroxyethyl)rutoside was shown by radioscanning and/or spectal methods. 4. Administration of a second oral dose of [14C]-HR to each of the three subjects following extended dosage of nonlabelled HR did not result in any increase in urinary [14C] excretion over that observed after administration of a single oral dose. 5. Observations on urinary excretion in man are compatible with the finding in experimental animals that the major route of hydroxyethylrutoside excretion is via the biliary-enteric route.

Administration, Oral↗